Published in Obesity and Diabetes Week, September 12th, 2005
XL999 and XL647 are anticancer compounds, currently in late phase I trials, and the company intends to begin a phase II program for each of these compounds before the end of the year. XL784 has completed a single-dose, phase I trial as well as additional toxicology and formulation development in preparation for a phase II program to test its utility in diabetic nephropathy.
Based on the specific targets of each compound, preclinical data, and insights gained during the phase I trials, the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.